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COMPREHENSIVE REVIEW
Chromodomain Helicase DNA-Binding Proteins
in Stem Cells and Human Developmental Diseases
Joseph A. Micucci,1 Ethan D. Sperry,2,3 and Donna M. Martin2–4
Dynamic regulation of gene expression is vital for proper cellular development and maintenance of differentiated
states. Over the past 20 years, chromatin remodeling and epigenetic modifications of histones have emerged as
key controllers of rapid reversible changes in gene expression. Mutations in genes encoding enzymes that modify
chromatin have also been identified in a variety of human neurodevelopmental disorders, ranging from isolated
intellectual disability and autism spectrum disorder to multiple congenital anomaly conditions that affect major
organ systems and cause severe morbidity and mortality. In this study, we review recent evidence that chro-
modomain helicase DNA-binding (CHD) proteins regulate stem cell proliferation, fate, and differentiation in a
wide variety of tissues and organs. We also highlight known roles of CHD proteins in human developmental
diseases and present current unanswered questions about the pleiotropic effects of CHD protein complexes, their
genetic targets, nucleosome sliding functions, and enzymatic effects in cells and tissues.
Introduction
Epigenetic modifier proteins are commonly dividedinto three classes: chromatin writers (eg, histone methyl-
transferases and acetylases), erasers (eg, histone demethylases
and deacetylases), and readers (eg, chromodomain and tudor
domain remodeling proteins). In this review, we focus on a
set of chromatin readers and an important family of ATP-
dependent helicase-containing DNA-binding proteins called
chromodomain helicase DNA-binding (CHD) proteins. We
review their structures, functions, and recently discovered roles
in stem cells and human diseases. Interestingly, CHD proteins
have been identified as critical regulators of cellular processes
such as stem cell quiescence, proliferation, and cell fate deter-
mination. In addition, they are implicated in a wide variety of
human disease processes, including autism, multiple organ
system development, and cancer. Finally, we synthesize recent
literature indicating that CHD proteins act at enhancer and pro-
moter regions of genes that regulate key developmental pro-
cesses, suggesting they orchestrate major cellular proliferation
and fate decisions. For reference, a summary of CHD proteins,
associatedmouse and human phenotypes, stem cells, interacting
proteins, and target binding sites is provided in Table 1.
Structure and Function of the CHD Superfamily
There are three major superfamilies of ATP-dependent
chromatin remodeling enzymes in eukaryotic organisms:
SWItch/Sucrose NonFermentable (SWI/SNF), Imitation
SWI, and CHD, each of which has a characteristic histone
interaction domain [1]. These chromatin remodeling en-
zymes interpret or read histone modifications through spe-
cialized protein domains that vary both between and among
the protein families. Upon reading the chromatin state, these
enzymes disrupt DNA–histone interactions by sliding nu-
cleosomes either along the DNA strand or by translocating
the nucleosome core particle to another DNA strand [2].
Ultimately, this chromatin remodeling function allows for
improved or reduced access to DNA by transcription factors
and other DNA-binding proteins that influence gene ex-
pression. The CHD family of ATP-dependent chromatin
remodeling enzymes comprises nine proteins divided into
three subfamilies based ondomainhomology (Fig. 1).AllCHD
proteins contain two tandem chromatin organization modifier
(chromo) domains and twoSucroseNonFermentable2 (SNF2)-
like ATP-dependent helicase domains [3,4]. The organization
of these domains and how they differ between CHD proteins
were recently reviewed [5]. In this study, we review highly
important functions of specific CHD proteins and protein do-
mains and focus on the roles of CHD proteins in stem cells and
human developmental disorders.
Chromodomains were originally identified in Drosophila
heterochromatin protein 1 (HP1). HP1 has a single chro-
modomain that binds nucleosomes to promote closed chro-
matin states (heterochromatin) and downregulate homeotic
genes during development [6–8]. Specifically, the HP1
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chromodomain facilitates protein–protein interactions with
the repressive histone modification H3K9me3, leading to the
formation of heterochromatin [6,9,10]. It is now understood
that the primary common function of chromodomains is
binding to methylated histone residues. Indeed, CHD
proteins contain a unique variant of the chromodomain
containing a methyl-binding cage that facilitates interac-
tions with lysine residue 4 of histone H3 (H3K4) [10,11].
CHD1 chromodomains (Fig. 1) interact with lysine 4 of
methylated histone H3 (H3K4me), and CHD5 chromodo-
mains bind to and maintain lysine 27 of trimethylated
histone H3 (H3K27me3) [11,12]. Thus, specific CHD
chromatin remodeling proteins exhibit unique functions
and preferences for repressive or active histone marks, and
the methyl-histone-binding chromodomains are essential
for maintaining dynamic chromatin structures and proper
gene expression.
The helicase–ATPase domains of CHD proteins are
highly similar to those observed in the SWItch2/SNF2
superfamily of ATP-dependent chromatin remodeling en-
zymes [3,13]. The helicase–ATPase domain functions as a
bilobed motor, which provides chemical energy and pro-
motes mechanical disruption of DNA–histone contacts.
This histone–DNA disruption leads to sliding of core his-
tones along the DNA template or core histone evacuation
and deposition onto another DNA strand [14–17]. Ad-
ditionally, the CHD subfamilies are delineated by the
presence of subfamily-specific protein domains (Fig. 1).
CHD1 and CHD2 contain DNA-binding domains, which
have been shown to be similar in function to SWI3, ADA2,
N-COR, and TFIIB (SANT) domains present in CHD6-9
[18]. The SANT domain confers nonspecific DNA binding,
particularly to linker DNA between nucleosomes [19–21].
Chromodomains in CHD1 exhibit preferential binding to
AT-rich sequences [22]. Compared with wild-type, recom-
binant CHD1 and CHD2 lacking the DNA-binding domain
lose the ability to bind both to DNA and to nucleosomes,
demonstrating the critical roles of CHD1 in nucleosome
targeting to DNA [18,23]. CHD3, CHD4, and CHD5 lack
DNA-binding domains, yet contain two tandem plant
homeodomains (PHDs) [24]. PHD domains are zinc finger
motifs that facilitate interactions with methylated histone
residues and protein cofactors, for example, between CHD3/
4 and histone deacetylase 1, which is part of the potent
negative transcriptional regulation Nucleosome-Remodeling
Deacetylase (NuRD) complex [25]. PHD domains confer
specificity to the target histone residues. For example,
binding of the two tandem PHD domains in CHD4 to H3K4
(unmodified) and H3K9me3 (but not to H3K4me3) mediates
the transcriptional repressive activity of CHD4/NuRD [26–
28]. In addition to the chromodomain and helicase domains,
CHD6–9 proteins also contain tandem BRahma Kismet
(BRK) domains that are also present in Drosophila Brahma
(brm), but the functions of these BRK domains are not
understood [29].
CHD Proteins and Embryonic Stem Cells
Regardless of the overall protein domain structure, the
function of CHD superfamily proteins is intimately tied to
regulation of gene expression through remodeling of nu-
cleosomes. Importantly, emerging trends across the entire
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CHD family include roles in the maintenance, survival, or
proliferation of stem cell populations and in directing cell
fate decisions of their progeny (Fig. 2). Embryonic stem
(ES) cells comprise a self-renewing and pluripotent cell
population from which the majority of mammalian tissues
are derived. ES cells can be viewed as a blank slate with an
open chromatin environment, becoming progressively
more differentiated toward neural, hematopoietic, mesen-
chymal, and other lineage-specific cells through activation
or repression of various genetic pathways. CHD1, the first
CHD protein implicated in stem cell function, was shown
to participate in Mediator complex regulation of ES cells
by maintaining open chromatin [30]. The Mediator com-
plex is a multiprotein complex responsible for preinitiation
of gene transcription that binds to CHD1 and recruits it to
actively expressed genes [31]. Specifically, CHD1 binds to
tracts of the active mark trimethylated histone H3 at the
residue lysine 4 (H3K4me3) and excludes the repressive
mark H3K27me3 [30]. When CHD1 is deleted in ES cells,
chromatin condenses to form heterochromatin and plurip-
otent differentiation is impaired potentially due to pro-
motion of ectodermal lineage gene expression at the
expense of endodermal lineage gene expression [30]. In
addition to its role in ES cells, CHD1 influences plur-
ipotency since induction of CHD1 expression is required
for efficient reprograming of mature fibroblasts into in-
duced pluripotent stem (iPS) cells [30]. Together, these
studies show that CHD1 is vital for maintaining plur-
ipotency in ES and other stem cells. By extension, CHD1
may also play an important role in establishment of the
pluripotent state, but this has yet to be formally tested.
Like CHD1, CHD7 has been implicated in several stem cell
populations and appears to be critical for regulating cell fate
decisions through modulation of signaling and epigenetic
pathways. The mouse Chd7 gene is highly expressed in ES
cells, where it appears to function similarly to CHD1 by as-
sociating with signals of active gene expression and open
chromatin at enhancer elements of critical stem cell plur-
ipotency genes, including Sox2,Oct4, andNanog [32].While it
is common for genes to be completely active or inactive in fully
differentiated cells, the euchromatic chromatin environment in
stem and progenitor cells is poised for either repression or
activation [33,34]. Unlike their active and inactive counter-
parts, poised enhancers and promoters typically display both
active and repressive marks [35]. CHD7 preferentially binds
active (H3K4me1+ , H3K27ac+ ) and poised (H3K4me1+ ,
H3K27me3+ ) enhancer elements at ectodermal lineage genes
in ES cells [32]. Thus, colocalization of CHD7 with poised
genetic elements presents a paradigmwherebyCHD7may play
a role in recruiting transcription factors, histone modifiers, and/
or other chromatin remodeling proteins in a cell type-specific
manner to promote activation or repression of certain classes of
genes through resolution of the poised chromatin state.
FIG. 2. CHD proteins function in a variety of stem cell
types. Shown, in colored circles, are the various stem cell
types and their associated CHD proteins, along with differ-
entiated cell lineages to which they contribute. Specific
functions (activation, inhibition) are omitted for simplicity or,
in some cases, because this information is not yet available.
FIG. 1. Cartoon of chromodomain heli-
case DNA-binding (CHD) proteins and
subfamilies. Shown are protein domains
with relative positions to the amino (left) and
carboxy (right) termini, not to scale. Adap-
ted with permission from Layman et al. [4].
CHD PROTEINS IN STEM CELLS 919
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CHD Proteins and Mesenchymal Stem Cells
Recent studies have provided evidence that CHD proteins
also regulate mesenchymal development (Fig. 2). Mesench-
ymal stem cells are multipotent mesoderm-derived cells that
give rise to myoblasts (muscle), adipocytes (fat), osteoblasts
(bone), and chondrocytes (cartilage) [36–38]. The differen-
tiation of mesenchymal stem cells into four distinct lineages
is regulated by several different CHD proteins. Induction of
myogenic cell fates requires the recruitment by CHD2 of a
chromatin destabilizing histone variant, histone H3.3, to
muscle differentiation genes, which then facilitates binding
and gene activation by the transcription factor MyoD [39].
Interestingly, CHD9, also known as chromatin-related mes-
enchymal modulator, binds to and promotes the expression of
osteocalcin (bone gamma-carboxyglutamate), one of the ma-
jor genes responsible for promoting bone development
[40,41]. Collectively, these observations emphasize the im-
portance of CHD family proteins in mesenchymal cell fate
decisions and highlight the basic principle that these proteins
can have diverse and potentially nonredundant functions
within the same stem cell type.
CHD Proteins and Hematopoietic Stem Cells
In addition to their roles in promoting development of
mesenchymal derivatives, one CHD protein (CHD4) has been
implicated in hematopoietic lineages (Fig. 2). The diverse cell
types present in blood are derived from common hemato-
poietic stem cell progenitors that reside in the bone marrow
and adopt one of two potential lineages: myeloid and lym-
phoid [42,43]. Myeloid lineage cells give rise to red blood
cells, platelet-producing megakaryocytes, and granulocyte
immune cells [42,43]. Lymphoid lineage cells give rise to the
agranulocytic natural killer, T-, and B-cells that also con-
tribute to the innate and adaptive immune responses [42,43].
CHD4, also known as Mi-2b, is an NuRD complex compo-
nent that has been shown to promote self-renewal and mul-
tilineage differentiation of hematopoietic stem cells [44].
Importantly, loss of the Chd4 gene in mouse bone marrow
leads to an abundance of erythroid progenitors and red blood
cells and to loss of lymphoid and remaining myeloid lineage
cell types [44]. Further examination of CHD4 activity in the
regulation of hematopoietic stem cells may provide novel
insights into mechanisms of human diseases such as cancers
affecting lymphoid lineage cells, including leukemia and
lymphoma. Functions for other CHD proteins in hematopoi-
etic cell types have not yet been reported.
CHD Proteins and Neural Stem Cells
Neural stem cells play a vital role in the development and
maintenance of the central nervous system and in sensory or-
gans by producing neurons and supporting cells such as glia and
oligodendrocytes. CHD4, CHD5, and CHD7 play pivotal roles
in the function and differentiation of neural stem cell niches in
the subventricular zone (SVZ)of the forebrain anddentate gyrus
of the hippocampus through cooperation with major epigenetic
modifiers, transcription factors, and signaling pathways. During
cortical neurogenesis, CHD4 is expressed inmurine SVZneural
progenitor cells and interacts with the Polycomb Repressive
Complex 2 (PRC2), specifically with the H3K27 methyl-
transferase enzyme, Enhancer of Zeste 2 [45,46]. The CHD4/
PRC2 complex directly binds to the promoter of the glial fi-
brillary acidic protein (GFAP) gene (Gfap), represses its ex-
pression, and prevents glial differentiation [46]. Through
inhibitionof theGfap locus,CHD4andPRC2promote neuronal
differentiation during the neurogenic period (between embry-
onic days 11 and 18 in mice) [46]. In addition to these roles for
CHD4 in neural stem cells, a recent study demonstrated that
CHD4andotherNuRDcomplex proteins actively repress genes
that inhibit neuronal differentiation in the cerebellum [47].
Thus, individual CHDproteins have important roles in stem cell
and differentiated cell populations, guiding decision making
and developmental progression at multiple stages.
Similar to CHD4, CHD5 also interacts with the PRC2 and
specifically associates with the repressive histone modifi-
cation H3K27me3 in neural stem cells [12]. CHD5 is highly
expressed in neural progenitor and neuroblast cells of the
SVZ and subgranular zone (SGZ) of the hippocampus,
which produces neurons that are important for learning and
memory [12]. Reduced Chd5 expression in the developing
cortex also leads to a significant loss of migratory neuro-
blasts [12], and Chd5-deficient neural stem cells exhibit
downregulation of genes responsible for neuronal migration
and maturation [12]. Taken together, these studies demon-
strate that CHD4 and CHD5 are critical for the inhibition of
glial differentiation during key neurogenic phases of mam-
malian brain development and suggest that chromatin re-
modeling is vital and dynamic during brain development.
CHD7 is another CHD protein that is enriched in and
critical for proper function of neural stem cells. Chd7 is
highly expressed in the SGZ of the hippocampus and the
SVZ of adult mice, where it colocalizes with markers of
neural stem cells (GFAP), neural progenitor cells (marked
by the transcription factor ASCL1), and neuroblasts (marked
by Doublecortin or DCX) [48,49]. Longitudinal studies in
mice with temporally induced conditional deletion of Chd7
in adult SVZ neural stem cells show that Chd7 deficiency
leads to a reduction in mature dopaminergic and GABAer-
gic olfactory bulb interneurons and reduced expression of
the proneural genes, Sox4 and Sox11 [49]. In the SGZ of the
hippocampus, conditional knockout of Chd7 also leads to a
reduction in neurogenesis, which can be rescued through
exercise [49]. In a recent study, Chd7 was also shown to
promote quiescence and maintenance of adult hippocampal
neural stem cell populations [50]. Considering that Chd7
also promotes neural stem cell progenitor proliferation in the
developing olfactory and otic placodes [51,52], these studies
provide convincing evidence that CHD7 is essential for stem
cell function in a variety of tissues. However, the precise
mechanisms by which CHD7 regulates stem cell prolifera-
tion, quiescence, fate, or differentiation, which binding
partners and genomic targets it associates with, and whether
these mechanisms vary between developmental and post-
natal stages remain to be determined. It is also not clear
whether differences in CHD7-mediated mechanisms of
neural development differ across the various neural stem
cell populations in the SVZ, SGZ, and sensory organs.
CHD Proteins in Human Disease
CHD7 and CHARGE syndrome
CHARGE syndrome (Coloboma, Heart defects, Atresia of
the choanae, Retardation of growth and development, Genital
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hypoplasia, and Ear abnormalities, including deafness and
vestibular disorders) is a multiple congenital anomaly con-
dition that occurs in approximately 1 in 10,000 live births
[53]. Heterozygous mutations in CHD7 are found in over
90% of individuals with CHARGE syndrome, suggesting that
it is a monogenic disorder with variable expressivity [54–56].
To date, there are no definitive genotype/phenotype correla-
tions, likely due to the tremendous diversity of CHD7 non-
sense, missense, deletion, and truncation mutations and the
highly variable expressivity of CHARGE features, even be-
tween members of the same family who have the same mu-
tation [56]. In vitro biochemical assays with recombinant
CHD7 protein have confirmed that CHD7 is an ATP-
dependent chromatin remodeling enzyme capable of modu-
lating DNA–histone interactions [57]. Interestingly, when
point mutations in the chromodomains from individuals with
CHARGE are introduced into recombinant CHD7, its ATP-
dependent chromatin remodeling enzymatic activity is re-
duced in a mutation-specific manner [57]. These studies
provide additional evidence for haploinsufficiency as the
major mechanism of CHARGE features. However, additional
functions of other CHD7 protein domains may still be dis-
covered and these new cellular functions, if they exist, may
help explain the wide variability in clinical features in indi-
viduals with CHD7 mutations.
In individuals with CHARGE syndrome, CHD7 hap-
loinsufficiency causes dysfunction in sensory processes and
impaired hearing, vision, balance, and olfaction. To more
fully understand the role of CHD7 in development and its
impact on sensory processes, mouse models have been
created and carefully analyzed. In our laboratory, a Chd7
gene trap null allele was generated through insertion of the
lacZ reporter into the Chd7 allele, creating a functionally
null allele with b-galactosidase reporter activity [58]. In-
terestingly, Chd7 null mouse embryos do not survive past
embryonic day 10.5, presumably from respiratory and
cardiovascular defects, while Chd7 heterozygous mice
display many of the same defects observed in CHARGE
[58]. Similarly, there have been no humans identified with
homozygous mutations in CHD7, suggesting that complete
loss of CHD7 (and perhaps other CHD genes) is embry-
onically lethal.
Chd7 is widely expressed in mammalian tissues, most
notably in those affected in CHARGE syndrome, including
the heart, inner ear, eye, olfactory epithelium, and brain
[4,58]. In each organ thus far analyzed, Chd7 expression has
been predictive of tissue or cellular defects in mutant mice.
In the inner ear, Chd7 heterozygous mice display hypoplasia
or aplasia of the lateral and posterior semicircular canals and
innervation defects of the vestibular sensory epithelium
[52,59]. Conditional knockout of Chd7 causes complete
aplasia of vestibular and cochlear structures, reductions in
fibroblast growth factor signaling, and decreased prolifera-
tion with reduced otic neural progenitors and reduced ex-
pression of proneural genes such as Ngn1 and Neurod1 [52].
These data indicate that CHD7 may function in some sen-
sory tissues similarly as it does in brain neural stem cells,
through regulation of critical molecular pathways that acti-
vate neurogenesis and inhibit gliogenesis.
Hyposmia and anosmia, reduction or loss of the sense of
smell, are two of the most highly penetrant phenotypes
observed in individuals with CHARGE. Olfactory deficits
are commonly accompanied by hypoplasia or aplasia of the
olfactory bulbs in the brain [55,60–62]. It was discovered,
through electrophysiological and behavioral assays, that
Chd7 heterozygous mice display complete anosmia, lack of
odor discrimination, and olfactory bulb hypoplasia [61,63].
Chd7 is highly expressed in olfactory epithelial neural stem
and progenitor cells, as demonstrated by colocalization with
Ascl1 and Neurod1 [61]. In mice, loss of Chd7 correlates
with a marked decrease in olfactory epithelial neural stem
cell proliferation, a subsequent reduction in olfactory sen-
sory neurons, and impaired recovery from damage [61].
Interestingly, Chd7 heterozygous mutant mice also show
decreased dopaminergic tyrosine hydroxylase-positive in-
terneurons in the olfactory bulb, which could be due to
impaired efferent signals from the olfactory epithelium or a
defect in olfactory bulb neurogenesis from the SVZ neural
stem cell niche [61]. Thus, olfactory processing depends on
CHD7 function not only in the peripheral olfactory epi-
thelium but also in central nervous system-derived neuro-
genic niches.
Coimmunoprecipitation and chromatin immunoprecipi-
tation studies have also shown that in neural stem cells,
CHD7 physically interacts with SOX2 at genes that are
associated with human diseases, including Alagille syn-
drome (caused by mutations in JAG1, a Notch signaling
ligand), Feingold syndrome (caused by mutations in
MYCN, a bHLH transcription factor), and Pallister–Hall
syndrome (caused by mutations in GLI3, a mediator of
Sonic hedgehog signaling) [64]. Several phenotypes ob-
served in these syndromes are also common in CHARGE
syndrome, including genital abnormalities (Pallister–Hall
and SOX2 deficiency), tracheoesophageal defects (Alagille,
Feingold, and SOX2 deficiency), pituitary and endocrine
dysfunction (Pallister–Hall and SOX2 deficiency), and
semicircular canal hypoplasia (Alagille). CHD7 binding to
SOX2 is intriguing due to the extensive overlap in ex-
pression and function of these two proteins and their
contributions to development of ectodermal lineages af-
fected in CHARGE, including the brain, retina, and neural
crest-derived cells, that populate the heart and craniofacial
tissues [65]. Together, these observations suggest that
CHD7 activity and protein–protein interactions may be
important for stem cell differentiation and cell fate deci-
sions in a wide variety of tissues and cell types.
CHD proteins in autism spectrum disorder,
intellectual disability, and epilepsy
Application of cytogenetic and next-generation sequenc-
ing technologies to large cohorts of individuals with autism
spectrum disorder (ASD), intellectual disability (ID), and/or
epilepsy has uncovered de novo and inherited heterozygous
frameshift, nonsense, or copy dosage mutations in several
CHD genes, including CHD2, CHD6, CHD7, and CHD8
[66–74]. For CHD2, CHD6, and CHD7, mutations identified
thus far are nonrecurrent (present in only individual cases),
private mutations that account for a small fraction of ASD/
ID/epilepsy cases. In contrast to the rare isolated mutations
in these three CHD genes, 13 different recurrent alleles of
CHD8 have been observed in individuals with ASD/ID in
association with macrocephaly and gastrointestinal distur-
bance [66,70,75–78]. In cultured cells, CHD8 has been
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shown to bind CHD7 and to both bind and regulate p53 and
inhibit its proapoptotic effects during development; thus, it
is surprising that loss of CHD8 is not associated with
broader phenotypic effects in humans [79–82]. Knockdown
of Chd8 by shRNA does not alter the morphology or neural
ectodermal markers of neural progenitors derived from
human iPS cells, but does significantly impair their gene
expression [74]. A very recent study also showed that CHD7
binds to and represses p53, suggesting some CHD proteins
(at least those in the third subclass) may share common
downstream mechanisms, interacting factors, and target
genes [83]. Thus, CHD7 and CHD8 not only share common
mechanistic pathways but also make unique contributions
to developmental events in a wide variety of tissues and
cell types.
Similar to CHD7 and CHD8 in ASD, CHD2 mutations
have been observed in individuals with epilepsy [66–68].
This raises the likelihood that the spectrum of human mu-
tations in CHD genes could be much broader than previ-
ously suspected. Given the complexities of CHD target
genes and interacting partners, a major research goal is to
clarify the exact mechanisms by which loss of CHD protein
function disrupts neural stem cell and/or neuronal/glial de-
velopment, and to determine exactly how this disruption
results in the complex developmental abnormalities in
CHARGE syndrome and the cognitive and behavioral pro-
files observed in ASD/ID and epilepsy. Such research could
uncover common underlying mechanisms that may also
potentially be targeted by therapies that directly or indirectly
modulate chromatin. Treatments might then be directed
toward altering the structure and/or function of synapses,
dendrites, axons, and signaling pathways that are critical for
proper progenitor, neuronal, and glial development.
CHD proteins in cancer and other disease
processes
In addition to the varied developmental roles for CHD
proteins in human biology, there are several other conditions
where CHD proteins have been implicated either through
genetic screens or analysis of tissue transcriptomic or bio-
chemical data. CHD1 was identified as frequently deleted in
the homozygous form in prostate cancer [84] and likely
contributes to cellular invasiveness [85]. CHD4/Mi-2b has
been found to be deleted in a high percentage (17%) of
endometrial cancers and is implicated as an autoantigen in
the inflammatory disorder dermatomyositis [86]. CHD5 is
unique among CHD proteins, in that it is highly enriched in
the nervous system and testis, and has been found to act as a
tumor suppressor in a wide variety of cancers, including
neuroblastoma, breast, ovarian, prostate, colon, and lung
cancer, and has been shown to regulate spermatogenesis
[87–89]. Notably, CHD6 mutations have been identified in
bladder [90] and colon cancers [91], consistent with roles for
CHD proteins in DNA damage repair and response path-
ways [92]. Analysis of gastric and colorectal cancers has
revealed mutations or altered expression of several CHD
proteins—CHD1, CHD2, CHD3, CHD4, CHD7, CHD8, and
CHD9—providing further evidence of the broad roles for
chromatin remodeling in cancer pathogenesis [93]. Some-
what surprisingly, scoliosis is also linked to disruptions or
sequence variants in CHD proteins, including CHD2 [94]
and CHD7 [95]. Together, these disease associations high-
light the wide variety of cells, tissues, and pathophysiolog-
ical processes that depend upon proper ATP-dependent
chromatin dynamics for normal function.
Conclusions
In this study, we have summarized CHD proteins and
recent evidence supporting their involvement in a variety of
stem cell types. Studies aimed at identifying CHD protein-
binding partners, target sites in the genome, and associated
disease mechanisms are active areas of research. CHD
proteins are emerging as critical contributors to health and
disease, with major functions during development of the
brain, eye, ear, heart, and skeletal systems. Future work
dedicated to uncovering the mechanisms whereby CHD
proteins mediate these effects are likely to reveal even more
interesting clues about this complex and intriguing class of
ATP-dependent chromatin remodelers.
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